Durect (NASDAQ: DRRX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Valuation and Earnings
This table compares Durect and Oramed Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Durect||$49.17 million||7.36||-$3.69 million||($0.03)||-78.67|
|Oramed Pharmaceuticals||$2.46 million||41.18||-$10.48 million||($0.79)||-8.92|
This table compares Durect and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
42.9% of Durect shares are owned by institutional investors. Comparatively, 2.6% of Oramed Pharmaceuticals shares are owned by institutional investors. 10.3% of Durect shares are owned by insiders. Comparatively, 27.5% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of current recommendations for Durect and Oramed Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Durect currently has a consensus price target of $2.83, suggesting a potential upside of 20.06%. Oramed Pharmaceuticals has a consensus price target of $22.50, suggesting a potential upside of 219.15%. Given Oramed Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Oramed Pharmaceuticals is more favorable than Durect.
Risk and Volatility
Durect has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Durect beats Oramed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Durect Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
Receive News & Ratings for Durect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Durect and related companies with MarketBeat.com's FREE daily email newsletter.